Protein kinases — the major drug targets of the twenty-first century?
Top Cited Papers
- 1 April 2002
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 1 (4) , 309-315
- https://doi.org/10.1038/nrd773
Abstract
Protein phosphorylation regulates most aspects of cell life, whereas abnormal phosphorylation is a cause or consequence of disease. A growing interest in developing orally active protein-kinase inhibitors has recently culminated in the approval of the first of these drugs for clinical use. Protein kinases have now become the second most important group of drug targets, after G-protein-coupled receptors. Here, I give a personal view of some of the most important advances that have shaped this field.Keywords
This publication has 58 references indexed in Scilit:
- The origins of protein phosphorylationNature Cell Biology, 2002
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal TumorNew England Journal of Medicine, 2001
- Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine KinaseScience, 2000
- SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin‐1Published by Wiley ,2000
- Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in YeastScience, 1991
- Potent selective inhibitors of protein kinase CFEBS Letters, 1989
- Inhibition of monocyte IL-1 production by the anti-inflammatory compound, SK&F 86002International Journal of Immunopharmacology, 1988
- Staurosporine, a potent inhibitor of phospholipidCa++dependent protein kinaseBiochemical and Biophysical Research Communications, 1986
- Discovery of A Ca2+‐and calmodulin‐dependent protein phosphataseFEBS Letters, 1982